ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1651 • ACR Convergence 2023

    Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

    Esther Vicente Rabaneda1, Pedro Martínez-Fleta2, Ana Triguero-Martínez2, Emilia Roy3, Miren Uriarte-Ecenarro4, Francisco Gutiérrez-Rodríguez4, Patricia Quiroga4, Ana Romero4, Nuria Montes2, Laura Esparcia Pinedo2, María Aranzazu Alfranca2, Rosario Garcia-Vicuna5, Francisco Sánchez-Madrid2, Isidoro González-Álvaro4 and Santos Castañeda5, 1Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 2Division of Immunology, Hospital Universitario de La Princesa, Madrid, Spain, 3Division of Internal Medicine, Hospital Universitario de La Princesa, Madrid, Spain, 4Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain

    Background/Purpose: Previous published works have raised the concern that methotrexate (MTX) might have a negative effect on immune response upon vaccine administration. At the beginning…
  • Abstract Number: 1728 • ACR Convergence 2023

    A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis

    Garth Blackler, James Akingbasote, Patti Kiser, Christopher Howlett, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada

    Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…
  • Abstract Number: 1744 • ACR Convergence 2023

    Histological and Molecular Comparison in the Synovial Tissue of Patients with Active Rheumatoid Arthritis to Remission

    Selina Ohl1, Klaus Frommer1, Markus Rickert2, Stefan Rehart3, Ulf Müller-Ladner1 and Elena Neumann1, 1Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 2Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, 3Dept. of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease which leads to local and systemic manifestations. Subsequently, the inflamed synovium drives the destruction of…
  • Abstract Number: 1760 • ACR Convergence 2023

    Methotrexate Augments the Release of Granulocyte-macrophage Colony-stimulating Factor from Activated Rheumatoid Arthritis Fibroblast-like Synoviocytes – Possible Consequences for Persistence of Joint Inflammation

    Beatrice Bergström1, Tilia Selldén1, Miriam Bollmann2, Mattias N.D Svensson1 and Anna-Karin Hultgård Ekwall3, 1University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 3University of Gothenburg, Kullavik, Sweden

    Background/Purpose: Activated fibroblast-like synoviocytes (FLS) are important mediators of synovitis and structural damage in rheumatoid arthritis (RA)[1]. Granulocyte-macrophage colony-stimulating factor (GM-CSF, encoded by the CSF2…
  • Abstract Number: 1815 • ACR Convergence 2023

    The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register

    Preeti Dhanasekaran1, Margaret Ma2, Manjari Lahiri2, Li Wearn Koh3, Stanley Angkodjojo4, Andrew Yu Keat Khor5, James Jiaqi Liu6, Stephanie Wong7 and Siaw Ing Yeo6, 1National University of Singapore, Singapore, Singapore, 2National University Hospital, Singapore, Singapore, 3Tan Tock Seng Hospital, Braddell Heights, Singapore, 4Sengkang General Hospital / Singhealth, Singapore, Singapore, 5Changi General Hospital, Singapore, Singapore, 6Singapore General Hospital, Singapore, Singapore, 7Tan Tock Seng Hospital, Singapore, Singapore

    Background/Purpose: To determine the association of body mass index (BMI) with incident COVID-19 infection in patients with inflammatory arthritis (IA) using biologic disease-modifying anti-rheumatic drugs…
  • Abstract Number: 1905 • ACR Convergence 2023

    Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic

    Rumey Ishizawar1, Thuyvan Phan2 and Steven Takacs3, 1University of North Carolina at Chapel Hill, School of Medicine, Division of Rheumatology, Allergy, and Immunology, Thurston Arthritis Research Center, Chapel Hill, NC, 2University of North Carolina Hospitals Department of Pharmacy, Apex, NC, 3University of North Carolina Faculty Physicians, Chapel Hill, NC

    Background/Purpose: The 2021 American College of Rheumatology (ACR) guidelines for the treatment of rheumatoid arthritis (RA) recommend a treat-to-target approach to optimize clinical outcomes. This…
  • Abstract Number: 2097 • ACR Convergence 2023

    Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque

    Natalia Guajardo-Jauregui1, Iris Colunga2, José Ramón Azpiri-López2, Dionicio A. Galarza-Delgado2, Rosa Arvizu-Rivera3 and Jesus Alberto Cardenas-De la Garza4, 1Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico

    Background/Purpose: Cardiovascular disease is the major cause of death in rheumatoid arthritis (RA) patients. Cardiovascular risk algorithms are employed to assess the likelihood of experiencing…
  • Abstract Number: 2114 • ACR Convergence 2023

    The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function

    Sho Fukui1, Wolfgang Winkelmayer2, Sara Tedeschi1, Javier Marrugo1, Hongshu Guan1, Leslie Harrold3, Heather Litman3, Tomohiro Shinozaki4 and Daniel Solomon5, 1Brigham and Women's Hospital, Boston, MA, 2Baylor College of Medicine, Houston, TX, 3CorEvitas, LLC, Waltham, MA, 4Tokyo University of Science, Tokyo, Japan, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA) affecting 10-20% of patients. However, the influence of the longitudinal RA disease…
  • Abstract Number: 2130 • ACR Convergence 2023

    Prevalence and Risk Factors of Pneumocystis Jirovecii Colonization in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors and Tocilizumab

    Yi-Min Huang1, Chieh-An Chuang2, Jui-Hung Kao2, Yen-Chun Lin2, Jen-Hao Chen3, Chiao-Feng Cheng4, Cheng-Hsun Lu4, Yu-Min Kuo4, Chieh-Yu Shen4, Chin-Hsiu Liu5, Ko-Jen Li4, Song-Chou Hsieh4, Jung-Yien Chien4 and Po-Ren Hsueh4, 1National Taiwan University Cancer Center, Taipei City, Taiwan, 2National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan, 3National Taiwan University Cancer Center, Taipei, Taiwan, 4National Taiwan University Hospital, Taipei, Taiwan, 5National Taiwan University Hospital, Taipei, Taiwan

    Background/Purpose: Patients with rheumatoid arthritis (RA) are susceptible toPneumocystis jiroveciicolonization and prone to develop life-threateningPneumocystispneumonia (PCP). An increased risk ofP. jiroveciicolonization and PCP was found…
  • Abstract Number: 2146 • ACR Convergence 2023

    After JAK Inhibitor Failure, “Switching” or “Cycling”?

    Pablo Francisco Muñoz Martínez1, Laura Mas Sanchez2, Elena Grau Garcia3, Carmen Riesco Barcena3, Anderson Victor Huaylla Quispe3, Alba Maria Torrat Noves3, Daniel Ramos Castro3, Belen Villanueva Mañez3, Iago Alcantara Alvarez3, Samuel Leal Rodriguez3, Elvira Vicens Bernabeu3, Jose Eloy Oller Rodriguez3, Ines Canovas Olmos3, Ernesto Tovar Sugrañes3, Carmen Najera Herranz3, Isabel Martinez Cordellat3, Hikmat Charia3, Rosa Negueroles Albuixech3, Marta De la Rubia Navarro2, Luis Gonzalez Puig3, Jose Ivorra Cortes3 and Jose Andres Roman Ivorra4, 1Rheumatology Department. HUP La Fe, Sagunto, Spain, 2Rheumatology Department. HUP La Fe, Valéncia, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Spain, 4Hospital Universitari i Politècnic la Fe, Valencia, Spain

    Background/Purpose: The appearance of JAK inhibitors (JAKi) in the last few years has proved a great clinical application in rheumatic pathology and it has become…
  • Abstract Number: 2163 • ACR Convergence 2023

    Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?

    Joy van der Pol1, Sytske Anne Bergstra2, Thomas Huizinga2 and CF Allaart2, 1Leiden University Medical Center, Utrecht, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The EULAR recommendations for the treatment of RA state, by expert opinion, that if a treatment target is not achieved with the first csDMARD…
  • Abstract Number: 2431 • ACR Convergence 2023

    Integrated Single Cell Multi-omics Analysis in At-Risk for Future Rheumatoid Arthritis (RA) and Early RA Reveals Shared Transcription Factor Profiles in Multiple Cell Lineages

    Cong Liu1, David Boyle1, Adam Savage2, Marie Feser3, Kristen Demoruelle3, kristine Kuhn4, Michael Holer3, kevin Deane3, Palak Genge2, Morgan Weiss2, Veronica Hernandez2, Julian Reading2, Jane Buckner5, Tom Bumol2, Mark Gillespie2, Peter Skene2, Wei Wang6 and Gary Firestein1, 1University of California San Diego, San Diego, CA, 2Allen Institute for Immunology, Seattle, WA, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4University of Colorado School of Medicine, Aurora, CO, 5Benaroya Research Institute at Virginia Mason, Seattle, WA, 6University of California San Diego, La Jolla, CA

    Background/Purpose: Identifying molecular signatures associated with anti-citrullinated protein antibody (ACPA) positive individuals who are 'at-risk' for future RA (At-Risk) and early RA (ERA) requires comprehensive…
  • Abstract Number: 2483 • ACR Convergence 2023

    CD68 and Fibrinoid Necrosis Are Synovial Biomarkers of Severity in Early Rheumatoid Arthritis and Are Associated with a Better Response to Methotrexate: Analysis of the UCLouvain Brussels ERA Cohort

    Francesco Natalucci1, clement triaille2, Emilie Sapart2, Cécile VAN MULLEM2, Tatiana Sokolova3, Laurent MERIC de BELLEFON2, Adrien NZEUSSEU TOUKAP2, Christine GALANT4, Bernard Lauwerys5 and Patrick Durez2, 1UCLouvain University, Sermoneta, Italy, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 3Université Catholique de Louvain, Brussels, Belgium, 4Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain), Anatomie pathologique, Brussels, Belgium, 5UCB Pharma, Brussels, Belgium

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with persistent synovial inflammation. Despite early diagnosis and the treatment-to-target strategy in ERA, the treatment response…
  • Abstract Number: 2584 • ACR Convergence 2023

    Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis

    Benoît Thomas P. GILBERT1, Raul Yhossef TITO TADEO2, Céline LAMACCHIA1, Olivia STUDER1, Delphine COURVOISIER1, Jeroen RAES3 and Axel Finckh4, 1Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 2Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium, 3Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven., Leuven, Belgium, 4HUG, Geneva, Switzerland

    Background/Purpose: We attempted to replicate and expand previous findings of an increased abundance of Prevotellaceae in early untreated Rheumatoid Arthritis (RA) or its preclinical stages,…
  • Abstract Number: 0002 • ACR Convergence 2023

    Population Pharmacokinetic and Pharmacodynamic Analyses of Obexelimab in Healthy Volunteers and in Patients with Rheumatoid Arthritis or IgG4-Related Diseases

    Xiaodong Wang, Rachel Kirk, Simon Lowry and Hua Mu, Zenas BioPharma, Waltham, MA

    Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefits across…
  • « Previous Page
  • 1
  • …
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology